Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency

Citation for published version:
Hammachi, F, Morrison, G, Sharov, AA, Livigni, A, Narayan, S, Papapetrou, EP, O'Malley, J, Kaji, K, Ko, MSH, Ptashne, M & Brickman, JM 2012, 'Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency', Cell Reports, vol. 1, no. 2, pp. 99-109.
https://doi.org/10.1016/j.celrep.2011.12.002

Digital Object Identifier (DOI):
10.1016/j.celrep.2011.12.002

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Cell Reports

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency

Fella Hammachi,1 Gillian M. Morrison,1,6 Alexei A. Sharov,2 Alessandra Livigni,1 Santosh Narayan,3 Eirini P. Papapetrou,4,7 James O'Malley,1 Keisuke Kaji,1 Minoru S.H. Ko,2 Mark Ptashne,3,* and Joshua M. Brickman1,5,*

1MRC Centre for Regenerative Medicine - Institute for Stem Cell Research, School of Biological Sciences, 5 Little France Drive, University of Edinburgh, EH16 4UU Edinburgh, UK
2Laboratory of Genetics, National Institute on Aging, NIH Biomedical Research Centre, 251 Bayview Boulevard, Suite 100, Baltimore, MD 21224, USA
3Molecular Biology Program, Memorial Sloan Kettering Cancer Center, 430E 67th St, New York, NY 10065, USA
4Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
5The Danish Stem Cell Centre - DanStem, University of Copenhagen, 3B Blegdamsvej, DK-2200 Copenhagen N
6Present address: The Wellcome Trust Centre for Stem Cell Research, University of Cambridge, Tennis Court Road, CB2 1QR Cambridge, UK
7Present address: Division of Hematology, University of Washington, 1705 NE Pacific St., Box 357710, Seattle, WA 98195, USA
*Correspondence: joshua.brickman@sund.ku.dk (J.M.B.), m-ptashne@mskcc.org (M.P.)
DOI 10.1016/j.celrep.2011.12.002

SUMMARY

Oct4 is an essential regulator of pluripotency in vivo and in vitro in embryonic stem cells, as well as a key mediator of the reprogramming of somatic cells into induced pluripotent stem cells. It is not known whether activation and/or repression of specific genes by Oct4 is relevant to these functions. Here, we show that fusion proteins containing the coding sequence of Oct4 or Xlpou91 (the Xenopus homolog of Oct4) fused to activating regions, but not those fused to repressing regions, behave as Oct4, suppressing differentiation and promoting maintenance of undifferentiated phenotypes in vivo and in vitro. An Oct4 activation domain fusion supported embryonic stem cell self-renewal in vitro at lower concentrations than that required for Oct4 while alleviating the ordinary requirement for the cytokine LIF. At still lower levels of the fusion, LIF dependence was restored. We conclude that the necessary and sufficient function of Oct4 in promoting pluripotency is to activate specific target genes.

INTRODUCTION

Cells that can differentiate into all adult cell types exist transiently in early embryos. When cultured in vitro, these pluripotent embryonic stem cells (ESCs) can self-renew indefinitely (Evans and Kaufman, 1981; Martin, 1981). Pluripotent, self-renewing cell lines, called induced pluripotent stem cells (iPSCs), can also be derived from somatic cells by transient ectopic expression of transcription factors that are normally expressed in ESCs (Takahashi and Yamanaka, 2006). The pluripotent state can be maintained in vitro by defined cytokines such as LIF (Smith et al., 1988; Williams et al., 1988) and BMP4 or serum (Ying et al., 2003) for mouse pluripotent cells. In particular, removal of LIF leads to spontaneous differentiation of mouse ESCs toward mesoderm and endoderm (Ying et al., 2003).

The class V Pou (PouV) transcription factor Oct4 is central to both the generation and the maintenance of iPSCs and ESCs. Thus, removal of Oct4 from ESCs causes these cells to differentiate into trophectoderm and primitive endoderm (Hay et al., 2004; Niwa et al., 1998; Niwa et al., 2000), and of the original four factors that together enable iPSC formation, (Oct4, Klf4, Sox2, and c-Myc) (Takahashi and Yamanaka, 2006), only Oct4 is essential regardless of the source of somatic cell (Kim et al., 2009). In mouse embryos, Oct4 is initially expressed in the inner cell mass (ICM) of the blastocyst but persists in the pluripotent epiblast and becomes progressively restricted to the posterior region of the embryo, where progenitor cells remain throughout gastrulation (Palmieri et al., 1994). Oct4−/− embryos die at preimplantation stages as a result of the differentiation of pluripotent ICM progenitors to trophectoderm (Nichols et al., 1998). Oct4 homologs in nonmammalian species are also expressed in gastrulation-stage progenitors, where they act to block precocious differentiation (Cao et al., 2006; Lavial et al., 2007; Lunde et al., 2004; Morrison and Brickman, 2006; Reim et al., 2004).

The Xenopus laevis PouV protein, Xipou91, can support murine ESC self-renewal of Oct4 null cells, and Oct4 mRNA can rescue some Xenopus PouV knockdown phenotypes (Morrison and Brickman, 2006). What gene-regulatory mechanisms are required to establish and maintain ESCs and iPSCs, and in particular, what role is played by Oct4?

Despite an abundance of data on Oct4 targets and phenotypes, it is still unclear how Oct4 acts as a transcription factor to regulate differentiation. Experiments with reporter genes in cell lines suggest that Oct4 can function as both an activator and a repressor of gene transcription (reviewed in Pan et al., 2002), and Oct4 has been found to be associated with both activator and repressor complexes (Ang et al., 2011; Bilodeau et al., 2009; Boyer et al., 2006; Pardo et al., 2010; Pasini et al., 2010; Yeap et al., 2009; Yuan et al., 2009).
module (Ohashi et al., 1994). PADALDDFDLDML is a single amino acid variant of an activating sequence found in VP16 (Baron et al., 1997). “Repeats” encoding a hinge region in lambda repressor C1 was inserted between Oct4 or XlPou91, added regulatory sequences, and repeated regulatory region from the Xl, their presumed activation strengths, referred to in the text as “weak,” “medium,” and “strong.” Abbreviations are as follows: m, murine; h, human; indicate the number of copies of the activation region in the corresponding fusion. The three OCT4-VP16 activation fusions are listed in the order of their presumed activation strengths, referred to in the text as “weak,” “medium,” and “strong.” Abbreviations are as follows: m, murine; h, human; Xi, Xenopus laevis.

| Fusion Protein | PouV Protein | Hinge | Transcriptional Regulatory Region | Repeats |
|----------------|--------------|-------|-----------------------------------|---------|
| Oct4-VP2       | mOct4        | λ C1 (91–132) | VP16 (413–460)                   | 2       |
| XiPou91-VP2    | XiPou91      | λ C1 (91–132) | VP16 (413–460)                   | 2       |
| OCT4-VP16      | hOCT4        | -      | VP16 (425–455)                   | 1       |
| OCT4-VP16      | hOCT4        | -      | VP16 (425–490)                   | 1       |
| OCT4-VP16 (3F) | hOCT4        | -      | VP16 (PADALDDFDLDML)             | 3       |
| Oct4:EnR       | mOct4        | λ C1 (91–132) | EnR (168–281)                    | 1       |
| XiPou91:EnR    | XiPou91      | λ C1 (91–132) | EnR (168–281)                    | 1       |
| OCT4-HP1α      | hOCT4        | -      | HP1α                             | 1       |
| OCT4-HP1β      | hOCT4        | -      | HP1β                             | 1       |
| OCT4-HP1γ      | hOCT4        | -      | HP1γ                             | 1       |

The human and mouse Oct4 genes and the Xenopus homolog XIPou91 were variously fused to one or more activating regions from VP16, to a repressing region from the Drosophila Engrailed protein, and to one of each of the three intact isoforms of the human protein HP1. In some cases a sequence encoding a hinge region in lambda repressor C1 was inserted between Oct4 or XIPou91, added regulatory sequences, and repeated regulatory modules (Ohashi et al., 1994). PADALDDFDLDML is a single amino acid variant of an activating sequence found in VP16 (Baron et al., 1997). “Repeats” indicate the number of copies of the activation region in the corresponding fusion. The three OCT4-VP16 activation fusions are listed in the order of their presumed activation strengths, referred to in the text as “weak,” “medium,” and “strong.” Abbreviations are as follows: m, murine; h, human; Xi, Xenopus laevis.

Genome-wide chromatin immunoprecipitation (ChIP) experiments, with both human and mouse ESCs, have detected Oct4 bound to numerous genes, some of which are expressed in ESCs and some of which are not (Boyer et al., 2005; Chen et al., 2008; Kim et al., 2008; Loh et al., 2006). Some of these genes become upregulated, and some downregulated, as ESCs differentiate in response to Oct4 knockdown (Sharov et al., 2008) (Loh et al., 2006). This finding has led to the suggestion that, in ESCs, OCT4/PouV and its partners Sox2 and Nanog simultaneously activate genes encoding components of a “pluripotency network” and, simultaneously, repress differentiation-specific genes (Bilodeau et al., 2009; Boyer et al., 2005; Boyer et al., 2006; Chen et al., 2008; Kim et al., 2008; Loh et al., 2006; Pasini et al., 2010). A contrasting suggestion is that Oct4 drives the expression of genes required for differentiation (and not for pluripotency) but this pathway is somehow blocked in ESCs by the conflicting effects of other genes (e.g., Nanog, Klf4, etc.) that attempt to promote differentiation along different pathways (Loh and Lim, 2011). One line of evidence purported to support this idea is that overexpression of Oct4, like its removal, causes ESCs to differentiate (Niwa et al., 2000).

Here, we study Oct4 derivatives designed to act exclusively as activators or repressors of transcription. Each protein bears the PouV DNA-recognition sequence fused to a strong transcriptional activation region (VP16 and derivatives thereof) or a strong repression region (Engrailed or HP1). We find that the activator, but not the repressor, fusions (along with other transcription factors) drive iPSC formation. The activator fusions, but not the repressor fusions, maintain the growth and pluripotency of murine ESCs lacking wild-type Oct4, and the activator fusions uniquely block differentiation of multipotent progenitor cells in Xenopus embryos. While maintaining ESCs in place of Oct4, an Oct4-activator fusion can render the pluripotent state both LIF-independent and immune to an “overexpression” phenotype (apparently by strongly activating key genes). We suggest that the activity of Oct4 as an activator is sufficient for the induction of iPSC formation and the maintenance of ESCs and embryonic progenitors.

RESULTS

Converting PouV Proteins to Activators and Repressors

Table 1 shows a series of fusion proteins, each with the DNA-binding specificity of Oct4 or XIPou91, designed to work exclusively as activators or as repressors. Genes encoding these proteins were constructed by fusing intact murine and human Oct4 and XIPou91 sequences, separately, to an activating region derived from mammalian VP16; to the repressing region of the Drosophila Engrailed (EnR); and to the mammalian heterochromatin protein HP1. In some cases the flexible hinge region of lambda C1 was interposed between the PouV protein and attached regulatory regions, an approach that has been particularly effective at converting full-length homeodomain repressors to activators (Brickman et al., 2001; Brickman et al., 2000; Zamparini et al., 2006). As a control, we also made fusions in which the DNA-binding domain was damaged by the mutation V267P (Niwa et al., 2002). We tested the activities of these fusion proteins with reporters introduced into the previously described murine ESC line ZHBTc4 (Niwa et al., 2000). Both endogenous copies of Oct4 have been deleted from these cells, and an Oct4 transgene, under control of a tetracycline (Tc)-repressible promoter, has been added. The cells grow as ESCs in the absence of Tc, and addition of Tc causes them to differentiate into trophoblast and primitive endoderm cells. In the absence of Tc, an introduced reporter gene bearing Oct4 binding sites is expressed, but by 24 hr after the addition of Tc, the introduced reporter fails to be expressed. mRNA and protein measurements confirm that the added Oct4 gene was essentially silent at this time. Within 96 hr after the addition of Tc, the cells have differentiated (Morrison and Brickman, 2006; Niwa et al., 2002; Niwa et al., 2000).
We cotransfected ZHBTc4 ESCs 24 hr after the addition of Tc with, separately, one of two different Oct4 responsive reporter genes (Niwa et al., 2002) and one or another of the Pou proteins listed in Table 1. One reporter contains the Oct4- and Sox2-dependent enhancer of the Fgf4 gene driving the TK promoter, and the other reporter contains six copies of a reiterated octamer-binding site. Both Oct4::VP2 and Xlpou91::VP2 efficiently activated both reporters, whereas Oct4::EnR and Xlpou91::EnR repressed basal expression. The fusion proteins neither activated nor repressed transcription from a reporter lacking any PouV protein-responsive elements. λVP2 and λEnR had little activity when fused to Oct4V267P (Niwa et al., 2002) (Figure S1).

**Activator Fusion Proteins Rescue Oct4 Null ESCs**

Figure 1B shows that exogenously added Xlpou91::VP2 and Oct4::VP2 maintained ZHBTc4 ESC growth in the absence of endogenous Oct4 (i.e., in the presence of Tc), whereas neither of the repressor fusions did so. The colonies depicted in the figure were generated by stable transfection of the ZHBTc4 ESCs with vectors expressing both the Pac gene (which renders cells resistant to puromycin) and one or another wild-type PouV proteins or PouV fusion protein under the control of the strong constitutive CAG promoter. The efficiency with which Oct4::VP2 supported Oct4 null ESCs (the rescue index, or normalized rescue efficiency) (Niwa et al., 2002) was equivalent to that obtained with wild-type Oct4. Although the rescue index for Xlpou91::VP2 was not as high as that obtained by Oct4::VP2, both proteins supported identical undifferentiated colony morphologies. Inspection of the rescued colonies suggests that Oct4::VP2 and Xlpou91::VP2 rendered the cells less likely to spontaneously differentiate than those rescued by wild-type Oct4 or Xlpou91. Thus, the latter displayed typical ESC colony morphology, with undifferentiated cells in the center and differentiated cells around the periphery (Figure 1C). In contrast, colonies rescued by the activator fusion proteins appeared undifferentiated throughout (Figure 1D). The mutant Oct4V267P, fused to either λVP2 or λEnR, was unable to support growth in the absence of Oct4 (Figure S2B). We also noted that colonies derived from stable transfection of ZHTBc4 with Oct4 or Xlpou91, in the absence of Tc, contained more differentiated cells than those in the presence of Tc (Figure 1C). This phenotype is consistent with the observation that overexpression (as well as underexpression) of Oct4 induces differentiation (Niwa et al., 2000). However, colonies derived from transfection of the activator forms of both proteins remained completely undifferentiated in the absence of Tc, a matter we return to below. Transfection of Oct4::EnR and Xlpou91::EnR into Oct4-expressing cells produced colonies composed largely of differentiated cells, as expected (Figure 1E). Similar completely undifferentiated colony morphologies were observed when Oct4::VP2 was introduced into the unrelated E14Tg2A ESC line (Figure S2C).

We further substantiated the rescue experiment just described by generating ZHBTc4 cell lines maintained by wild-type Oct4 and, separately, by Oct4::VP2 and by Xlpou91::VP2. Colonies like those in Figures 1C and 1D were expanded for at least five passages in the presence of constant puromycin and Tc. The Oct4::VP2- and Xlpou91::VP2-supported cultures had fewer differentiated cells than did those supported by wild-type Oct4 (Figure S4A). In both cases we examined multiple independent clonal cell lines to assure that ESC phenotypes were not the result of isolated karyotypic changes. As Oct4::VP2 and Xlpou91::VP2 expressing cell lines appeared identical, we focused on Oct4::VP2-supported cell lines. Four different Oct4::VP2-supported cell lines were also confirmed to have normal karyotypes (data not shown). We found that these cell lines self-renewed as efficiently as Oct4-supported lines, as assayed by assessment of the capacity of single cells to generate ESC colonies (Figures S4B and S4C). No difference in proliferation or plating efficiency was detected when these lines were compared to either ZHBTc4 or the unrelated ESC line E14Tg2A (Figure S4D). ESCs supported by Oct4::VP2, like ZHBTc4 and E14Tg2A cells, expressed the ESC transcription factors Nanog, Sox2, and Oct4 and the cell-surface markers SSEA-1 and E-cadherin (Figure 3B, S4E, and S4F).

**Activator Fusion Proteins Induce Pluripotency**

As noted in the Introduction, Oct4 is typically required, along with other transcription factors, to induce reprogramming of somatic cells to iPSCs in vitro. We tested the ability of various PouV-activator fusions and -repressor fusions to substitute for wild-type Oct4 in such a reprogramming experiment. We were able to generate both human and murine stable iPSCs by using activator, but not, where tested, repressor fusions (Figures 2A and 2B). The mouse iPSCs in Figure 2A were generated with the use of a single piggyBac transposon that bears the Sox2, Klf4, and c-Myc genes, as well as either wild-type Oct 4 or Oct4::VP2, all under control of a Tc-inducible promoter (Kaji et al., 2009). Although the timing of the appearance of ESC-like iPSC colonies after transfection and addition of the Tc analog Doxycycline (Dox) was comparable in the two cases, the Oct4::VP2 colonies grew faster than did their counterparts containing wild-type Oct4 (Figure 2A). The Oct4::VP2-derived iPSC colonies were expanded in the presence of Dox. As expected for iPSCs, growth became independent of the exogenous genes, as indicated by growth in the absence of Dox (Figures S5A and S5B). When Oct4::VP2-induced iPSCs were transplanted into adult mice, they formed teratomas containing derivatives of all three germ layers (Figure S5C), a further indication of pluripotency. To generate human iPSCs, we infected human fibroblasts with lentiviral vectors expressing the three additional factors (all human)
plus either wild-type human OCT4 or OCT4 fusion proteins (Figure S3) (Papapetrou et al., 2009). Figure 2B shows that three OCT4-repressing fusions eliminated iPSC formation and that two activating fusions labeled “weak” and “medium” (see Table 1 legend) substituted efficiently for wild-type OCT4. The activator fusion labeled “strong” worked somewhat less efficiently than did its weaker counterparts, but Figure 2C shows that decreasing its concentration improved its activity in this assay. Thus, OCT4-activator fusions, but not repressor fusions, promote iPSC formation.

**Gene Expression in Activator-Induced and -Maintained Pluripotent Cell Lines**

**Murine ESC Lines**

We used microarrays to compare the transcriptional profiles of ESCs maintained, respectively, by wild-type Oct4 and by Oct4VP2. A set of genes directly or indirectly responsive to wild-type Oct4 was previously determined by measuring changes in gene expression after knockdown of endogenous Oct4 (by adding Tc to the parental ZHBTc4 ESCs) (Sharov et al., 2008). Putative direct targets of Oct4, from among these genes, were identified as being rapidly responsive and having at least one Oct4 binding site in the vicinity of the transcription start site on the basis of the ChIP-PET method. Of the 372 putative Oct4-dependent targets (from Sharov et al., 2008), some 94% were expressed at normal or higher levels in Oct4VP2-maintained cells. Expression of the remaining 6% (23 genes) was reduced more than 2-fold. 

---

**Figure 1. Actions of PouV-Activator and -Repressor Proteins**

(A) In situ assays for the mRNA products of Mixer, Sox17, and BMP4 were performed on stage 10.25 embryos after injection of Xlpo91, Xlpo91VP2, or Xlpo91EnR mRNA at the two-cell stage into both blastomeres. The images are from the vegetal pole (top two rows) and the animal pole (bottom row). (B) The relative numbers of cells rescued by the indicated regulators is shown as the rescue index. Each transfection was divided, and half of the cells were plated in the presence of Tc and the rest in its absence. The rescue index was calculated by dividing the number of alkaline phosphatase (AP)-positive colonies obtained in the absence and presence of Oct4 (± Tc). Data represent the mean values obtained from three independent experiments. (C–E) Morphology of ESC colonies supported by wild-type PouV proteins (C), activator fusions (D), and repressor fusions (E). The colonies were generated by stable transfection of the ZHBTc4 ESCs with vectors expressing one or another wild-type PouV or PouV fusion proteins and the Pac gene (which renders cells puromycin resistant) from an internal ribosome entry site (IRES) in the same message, all under the control of the strong CAG promoter. Constitutive expression of the exogenous fusion proteins in the absence of Oct4 was selected on the basis of Puromycin resistance in the presence of Tc. Cultures were stained for AP (red).
with the use of the experimental setup depicted in Figure S3C. In brief, the OCT4 or OCT4 fusion proteins with vexGFP. The efficiency was calculated mCitrine, KLF4 with mCherry, cMYC with mCerulean, and either wild-type bicistronic vectors coexpressing each reprogramming factor, linked by a P2A (B) OCT4 activator fusions support human iPSC generation. MRC-5 human transfection in the presence of the Tc analog Dox. MEFs were transfected with programming factors (cMyc, Klf4, and Sox2) at days 5, 9, 18, and 24 after transduction. MEFs were transduced as in (A) Morphology of colonies resulting from mouse embryonic fibroblasts (MEF) transfection with either wild-type Oct4 or Oct4VP2 alongside the other reprogramming factors (cMyc, Klf4, and Sox2) at days 5, 9, 18, and 24 after transfection in the presence of the Tc analog Dox. MEFs were transfected with a piggyBac transposon bearing a single-message multigene expression cassette under the control of a Tc-inducible promoter. (B) OCT4 activator fusions support human iPSC generation. MRC-5 human embryonic fibroblasts were transduced with combinations of four lentiviral bicistronic vectors coexpressing each reprogramming factor, linked by a P2A peptide, to a fluorescent protein (Papapetrou et al., 2009); SOX2 together with mCitrine, KLF4 with mCherry, cMYC with mCerulean, and either wild-type OCT4 or OCT4 fusion proteins with vexGFP. The efficiency was calculated with the use of the experimental setup depicted in Figure S3C. In brief, the number of Tra-1-81 colonies (scored by immunostaining on day 15 after transduction) per number of plated cells divided by the fraction of quadruple positive cells as estimated by flow cytometry on day 2 after transduction. (C) Lower levels of the strong activator (OCT4-VP16 [3F]) work more efficiently in iPSC formation. MRC-5 human embryonic fibroblasts were transduced as in (B) with the use of 3-fold titrations of the vector expressing either wild-type OCT4 or OCT4-VP16 (3F) and constant amounts of the other three vectors (SOX2, KLF4, cMYC). The reprogramming efficiency was calculated as in (B). See also Figure S3C and its associated legend.

Figure 2. Oct4-Activator Fusions Support iPSC Generation

(A) Morphology of colonies resulting from mouse embryonic fibroblasts (MEF) transfection with either wild-type OCT4 or OCT4-VP2 alongside the other reprogramming factors (cMyc, Klf4, and Sox2) at days 5, 9, 18, and 24 after transfection in the presence of the Tc analog Dox. MEFs were transfected with a piggyBac transposon bearing a single-message multigene expression cassette under the control of a Tc-inducible promoter. (B) OCT4 activator fusions support human iPSC generation. MRC-5 human embryonic fibroblasts were transduced with combinations of four lentiviral bicistronic vectors coexpressing each reprogramming factor, linked by a P2A peptide, to a fluorescent protein (Papapetrou et al., 2009); SOX2 together with mCitrine, KLF4 with mCherry, cMYC with mCerulean, and either wild-type OCT4 or OCT4 fusion proteins with vexGFP. The efficiency was calculated with the use of the experimental setup depicted in Figure S3C. In brief, the number of Tra-1-81 colonies (scored by immunostaining on day 15 after transduction) per number of plated cells divided by the fraction of quadruple positive cells as estimated by flow cytometry on day 2 after transduction. (C) Lower levels of the strong activator (OCT4-VP16 [3F]) work more efficiently in iPSC formation. MRC-5 human embryonic fibroblasts were transduced as in (B) with the use of 3-fold titrations of the vector expressing either wild-type OCT4 or OCT4-VP16 (3F) and constant amounts of the other three vectors (SOX2, KLF4, cMYC). The reprogramming efficiency was calculated as in (B). See also Figure S3C and its associated legend.

See also Figure S3C and its associated legend.

Among these 23 there were only two genes with known pluripotency-related activity: Sall4 and Lefty1. Most genes associated with differentiation (e.g., Cdx2, Eomes, Fgf5, Gata6, Gata3, Igf2, Hand1, Esx1) were either reduced or expressed at normal levels (Table S1). All other pluripotency-related genes were expressed at either normal or higher levels in Oct4xVP2-rescued cells (Table S1, Figure 3B; also see Figure S7), with a small set of primordial germ cell and pluripotency markers expressed at levels greater than 2-fold above wild-type cells, including Gdf3, Dppa2, Dppa3 (Stella), Eras, Tcfcp21, Idf3, Fbxo15, Sox15, and Nanog. Nanog was expressed at an average of 2- to 5-fold higher than in ordinary ESCs, and its distribution was more homogeneous (Figure S4E). Gene ontology (GO) annotations of the upregulated and downregulated genes in the Oct4xVP2 cell line with more than 2-fold changes are listed in Table S2. While there does not appear to be a single biological process common to the upregulated genes in Oct4xVP2 cells, the downregulated gene set was enriched in functions associated with embryonic development and differentiation. These GO terms include a list of developmental transcription factors, cell differentiation, system development, epithelial differentiation, sex differentiation, cell migration, Wnt signaling, and several categories related to neural development.

Murine and Human iPSC Lines

Endogenous pluripotency genes, including Oct4, Klf4, Sox2, and c-Myc, were expressed in murine iPSCs generated from fibroblasts with Oct4xVP2 (plus the other three factors) (Figure 3C, Figure S5). Expression of Nanog and Dppa4 at early times after transduction of human fibroblasts with OCT4 fusions was increased by increasingly stronger versions of OCT4xVP2 (Figure 3D). These markers were only modestly induced at this early time point by wild-type OCT4, and not at all by OCT4-HP1.

ESCs Rescued and Maintained by Activator Fusions Are Resistant to Differentiation

Overexpression of Nanog has been reported to counter the induction of differentiation as a result of LIF removal (Chambers et al., 2003). Consistent with these findings, our Oct4xVP2-supported murine ESCs, which overexpress Nanog, are able to grow in the absence of LIF, as shown in Figure 4A. Oct4xVP2-maintained ESC lines were AP positive and exhibited undifferentiated ESC morphology when grown with or without LIF. These cells did, however, grow more slowly in the absence of LIF than in its presence (Figure 4 and Figures S6B and S6C). To better understand the response of Oct4xVP2-supported cells to LIF, we compared mRNA from Oct4xVP2-rescued cell lines and two sets of control lines (Oct4-rescued and the parental ZHBt4C cells) in response to LIF withdrawal (Figures 4B and 4C, Table S3, and Figure S6). LIF withdrawal caused similar changes in gene expression in the latter two lines, with a single set of genes decreased (cluster a, Figure 4B) and a second set increased (cluster b, Figure 4B). However, LIF withdrawal from Oct4xVP2-maintained cell lines caused little change in expression of genes in either set. For example, expression of the pluripotency genes Nanog, Klf4, Sox2, and Rex1 was downregulated in the control cells after LIF withdrawal, but their expression was unaffected in Oct4xVP2-maintained cells. The endodermal markers Gata4 and Gata6, upregulated upon LIF withdrawal
Figure 3. Oct4 Activator Fusions Induce and Maintain the Expression of Pluripotency-Related Genes

(A) Oct4 VP2 enhances the expression of Oct4-positively-regulated genes and inhibits the expression of those genes negatively regulated by Oct4. We compared the total set of genes changing when Oct4 VP2-supported cells were compared to controls, to the complete set of genes responsive to Oct4. The majority of these genes (94%) were expressed at normal (around the x axis) or higher than normal (above the x axis) levels in Oct4 VP2 cells. The basis for this plot was the difference between the log expression of genes in Oct4 VP2 cells and the average log expression in both controls, plotted against the maximum gene expression change (log ratio) in a time course after Oct4-Tc silencing (addition of Tc) in ZHBTc4 ESCs (the time course data from Sharov et al., 2008). Genes with < 1.5-fold change of expression after Oct4-Tc silencing are not shown. Oct4-dependent genes that also contain Oct4, Nanog, and Sox2 binding sites are indicated as targets (light blue or purple; see Sharov et al., 2008).

(B) Expression of pluripotency genes in Oct4 VP2-rescued cells. Expression levels of pluripotency-related genes including Nanog, Sox2, Klf4, and Rex1 were determined by qRT-PCR. Expression levels of all analyzed genes were normalized to TBP levels for each sample.

(C) iPSCs generated with the use of Oct4 VP2 express levels of pluripotency markers similar to those of normal iPSCs. Expression levels of a range of pluripotent cell markers were assessed by qRT-PCR. Nanog, Fgf4, Rex1, Dppa4, and Eras expression is shown in wild-type Oct4 and Oct4 VP2 iPSCs. Duplicate bars represent independent iPSC lines. Expression levels were normalized to TBP levels for each sample. Key indicates the Oct4 protein used for reprogramming. E14 (embryonic day 14) Tg2a ESCs and MEFs were used for the sake of comparison.

(D) Wild-type Oct4 and its activator fusions, but not OCT4-HP1 repressor fusions, induce immediate early expression of pluripotency markers, NANOG and DPPA4. MRC5 human embryonic fibroblast cells were harvested 48 hr after viral transduction for mRNA analysis. Expression levels in an iPSC line generated with the use of wild-type forms of all four factors are shown for comparison. Levels of gene expression are relative to RPL7 and normalized to nontransduced control.
from typical ESCs, remained unaffected by LIF withdrawal from Oct4\textsubscript{LIF}-supported ESCs. Expression of certain mesoderm markers that are normally expressed alongside Oct4 in the primitive streak (e.g., \textit{Brachyury} and \textit{Wnt 3}) were increased after LIF removal from Oct4\textsubscript{LIF}-supported cells (Figure 4C and Figure S7). When examined globally, there was a striking negative correlation between the set of genes that normally respond to LIF and those expressed at high levels in Oct4\textsubscript{LIF}-maintained cells grown in the absence of LIF (comparison based on average log ratio, \( r = 0.695 \), \( t = 153 \), \( p < 0.0001 \); also see Figure S6G).

Despite the robust expression of \textit{Nanog} and other pluripotency-related genes in Oct4\textsubscript{LIF}-maintained ESCs, and the conferred LIF independence just described, the expression of Oct4\textsubscript{LIF} itself was 2- to 5-fold lower than that of Oct4 in ESCs maintained by wild type Oct4 (Figure 4D, Figure S4E). We repeated the original Oct4\textsubscript{LIF}-rescue experiment to generate new stable cell lines (see Figure S4A), adding the same amount of Tc to the medium but a reduced amount of pyr3yn. This reduced stringency of selection enabled the isolation of new Oct4\textsubscript{LIF}-supported cell lines (Oct4\textsubscript{LIF}*) which expressed even lower levels (from 1.4- to 2-fold mRNA and/or protein) of Oct4\textsubscript{LIF} and Nanog. Western blots comparing expression levels of Oct4 and Nanog in the different rescued cell lines are shown.

Upon removal of LIF, these cells differentiated to extents similar to those of wild-type Oct4-rescued ESCs and parental ZHBTc4 control cell lines (Figure 4E). Colonies generated from clonal growth of Oct4\textsubscript{LIF}* cell lines appeared similar to wild-type Oct4-supported cell lines, both forming differentiated cells at the periphery (Figures S8A and S8B) and both sensitive to the differentiation-induced effect of Oct4 overexpression (Figure 4E).
DISCUSSION

Our findings support the idea that the necessary and sufficient action of Oct4 in inducing iPSC formation, and in blocking differentiation in vitro and in vivo, is to directly activate (rather than directly repress) expression of specific target genes. Thus, in both mouse ESCs and Xenopus embryos, PouV/Oct4-repressor fusion proteins induced differentiation, whereas the activator forms maintained the undifferentiated pluripotent state. Our results are consistent with a “positive only” model (based on a different line of experimentation) for maintenance of pluripotency of ESCs (Chamberlain et al., 2008).

Moreover, the Oct4-activator fusions, but not the -repressor fusions (along with additional transcription factors), induced iPSC formation. Analysis of gene expression profiles revealed that Oct4-activator fusions specifically enhanced expression of many genes identified as required for pluripotency, but not of genes that drive differentiation. One of our ESC lines (see below) maintains its ESC state even after withdrawal of LIF. These cells do not differentiate in response to additional Oct4 and thus do not display the usual Oct4 overexpression phenotype. These results are consistent with recent reports that claim enhanced pluripotency gene regulators (Chew et al., 2005; Hall et al., 2006; Sharov et al., 2008). We found that increasing the activating region strength of the Oct4 fusions (bearing VP16 derivatives), as well as increasing the concentration of one of them, resulted in higher levels of Nanog expression, suggesting that Oct4 directly activates Nanog as part of this loop.

How, then, would we rationalize this proposal with findings and models of others? First, we note the importance attributed by Loh and Lim (2011) to the finding that overexpression of Oct4 causes differentiation, a result taken to imply that Oct4 activates genes required for differentiation, not for pluripotency. But overexpression experiments can be difficult to interpret. An activator works in a concentration-dependent manner, binding to proper DNA sites (usually with other proteins) over a certain concentration range and then, at higher concentrations, binding less specifically to DNA. And, by virtue of protein-protein interactions, an overexpressed activator can inhibit (squelch) the effect of other activators and even its own action (Gill and Ptashne, 1988; Ptashne, 2009). Indeed, it has been reported that overexpression of Oct4 lacking a functional DNA-binding domain induces ESCs to differentiate (Niwa et al., 2002), a result indicating that the phenotype is not directly attributable to the ordinary action of Oct4.

In our experiments, any side effects of overexpression evidently have been eliminated by the use of the strong activator fusions. Thus, in a line of ESCs maintained by Oct4:VP2, the level of the Oct4:VP2 protein is low, significantly lower than that of wild-type Oct4 found in the typical ESC. These cells express high levels of select pluripotency factors, including Nanog, and are resistant to the ordinary inducing effect of differentiation upon LIF removal. These cells also, unlike ESCs maintained by exogenously added Oct4, do not differentiate when additional Oct4 is expressed. Another line, selected to express even lower levels of the activator, behaves like a typical ESC, subject to differentiation upon LIF removal, despite the very low level of expression of the activator fusion, and this line differentiates upon expression of additional Oct4.

Second, we note the importance given to genome-wide ChIP experiments showing that, in ESCs, Oct4 can be found bound to regulatory elements at certain genes that are not expressed—these genes become expressed upon differentiation. But lacking further analysis, these purported facts do not show that Oct4 is working as a repressor at those genes. Perhaps Oct4 is bound to genes in a nonfunctional state, awaiting relief from, or addition of, some partner to work. Polycomb, for example, is found at many silent genes in ESCs, but its removal has little effect on the maintenance of pluripotent gene expression (Schoeftner et al., 2006), and there are indications that polycomb remains at these genes during very early steps in differentiation (J.M.B. and W.A. Bickmore, unpublished data). There may be a misleading assumption at work here, namely that for a gene to be “off” it must be actively repressed. Though this is true for most genes in bacteria, it is not true in general for genes in eukaryotes. In bacteria, specific repressors are required to eliminate an otherwise significant basal level expression upon...
removal of activators, but this is evidently not true for eukaryotic genes. Rather, it seems, the general inhibiting effect of nucleosomes maintains basal expression at very low levels (Struhl, 1999; Wang et al., 2011b). Thus, without activators that would turn on the differentiation genes, there would be no need for repressors to turn them off. And so in ESCs, where activators maintain expression of pluripotency genes, differentiation genes could simply be off (by default, as it were) until activated by some activators that are rendered functional by virtue of gain (or loss) of a signal.

EXPERIMENTAL PROCEDURES

ESCs were cultured on 0.1% gelatin-coated flasks or plates (IWAKI) in Glasgow modified Eagle’s medium (GIBCO) containing nonessential amino acids, glutamine, sodium pyruvate, 0.1 mM mercaptoethanol, 10% fetal calf serum (FCS), and LIF as described previously (Livigni et al., 2009; Morrison and Brackman, 2006). LIF withdrawal and Oct4 overexpression was performed according to Morrison and Brackman (2006). For ESC self-renewal rescue experiments, 2 × 10³ ZHBTc4 ESCs were electroporated with 100 µg of linearized plasmid DNA followed by culture with or without 2 µg/ml Tc (Sigma) for 2 days. Cells were then cultured in 2 µg/ml puromycin (Sigma) with or without Tc for 7 days. The resulting colonies were stained for alkaline phosphatase (AP) activity (Sigma-Aldrich) or expanded as clonal lines (Morrison and Brackman, 2008). The cDNAs used for ESC rescue were inserted into pCAGIP vector (Niwa et al., 2002; Niwa et al., 1991).

 Luciferase assays were performed as described previously (Brickman et al., 2001; Morrison and Brackman, 2006). ZHBTc4 ESCs (1 × 10³) were plated on a 24-well plate with 2 µg/ml of Tc. Twenty-four hours after plating, the reporter and test plasmid were transfected with the use of Lipofectamine 2000 (Invitrogen). Twenty-four to forty-eight hours after transfection, the cells were collected and lysed, and luciferase assay was performed with the Dual-Luciferase Reporter Assay System (Promega). Reporter plasmids were a kind gift from Professor Hitoshi Niwa (Riken Institute, Japan) (Niwa et al., 2002). The expression vector used was the pCAG-IP plasmid.

Growth rates were assessed in 96-well plates with CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). A total of 1,000 cells were plated per well and assayed every 24 hr according to the manufacturer’s instructions. AP staining was performed with the Leukocyte Alkaline Phosphatase Assay Kit (Sigma).

For antibody staining, cells were washed twice in PBS, followed by fixation in 4% paraformaldehyde. Cells were then permeabilized in PBS + 0.1% Tween 20 (PBST), and blocking was performed by adding 1% bovine serum albumin (BSA) (Sigma) PBST to the cells for 30 min at room temperature. Primary antibodies (see Table S4 for details) were incubated overnight at 4°C, followed by three washes in PBST for 10 min each. Alexa Fluor-conjugated secondary antibodies (see Table S4 for details) were diluted in blocking solution and added to the cells for 3 hr at room temperature with the DAPI solution. Finally, cells were washed three times in PBST.

Flow cytometry was used to analyze the percentage of ESC clones expressing the cell-surface markers SSEA1 and E-Cadherin (for the antibodies, see Table S4). Cells were collected into the cell-dissociation buffer (GIBCO) and washed three times in PBST. Finally, cells were washed three times in PBST for 10 min each. Alexa Fluor-conjugated secondary antibodies were added to the cells. Samples were analyzed in a FACS-Calibur flow cytometer (BD Biosciences). Data were analyzed with the Cell Quest software (BD Biosciences).

For qRT-PCR analysis, total RNA was prepared from cells with the use of Trizol reagent (Invitrogen). RNA (0.5–1 µg) was used as a template for cDNA synthesis with the use of Superscript III (Invitrogen). qRT-PCR was performed with the use of a LightCycler 480 (Roche). Primers and PCR conditions are listed in Table S5. Embryo injection, culture, and in situ hybridization were described in Zampanini et al., 2006 and Morrison and Brackman, 2006. To generate RNA for injections, pC52+ plasmids harboring the target cDNAs Xpou91/Vp2, Oct4/Vp2, Xpou91/EnR, Oct4/EnR, Oct4, and Xpou91 were linearized with BsaHII and used as a template for RNA synthesis with SP6 polymerase (Promega). Total RNA was prepared from five embryos with the RNeasy Mini Kit (QIAGEN) and DNaseI treatment. RNA (500 ng) was used as a template for cDNA synthesis with Superscript III (QIAGEN). Real-time PCR was carried out with a Lightcycler 480 (Roche). Real-time PCR primers are listed in Table S5.

For microarray analysis, two independent clones from each cell line were used as biological replications. Cy3-CTP-labeled sample targets were prepared from 2.5 µg of total RNA with the use of a Low RNA Input Fluorescent Linear Amplification Kit (Agilent). Cy5-CTP-labeled reference target was produced from 2.5 µg of Stratagene Universal Mouse Reference RNA. Purified target RNAs were hybridized to the NI-A Mouse 44K Microarray version 3.0 (whole-genome 60-mer oligo arrays, Agilent Technology, design ID 015087) (Carter et al., 2005) according to the manufacturer’s protocol (Two-Color Microarray-Based Gene Expression Analysis Protocol, version 5.0.1). Data were analyzed via NIA Array Analysis (Sharov et al., 2005) under standard statistical conditions (FDR < 0.05, 2-fold expression level change).

For mouse iPSC generation, PiggyBac transposons containing Oct4 and Oct4/Vp2 were constructed as described previously (Kaji et al., 2009). Mouse embryonic fibroblasts (MEFs) were isolated from 13.5 dpc (days postcoitum) ROSA26 knockin rTATA-RES-GFP embryos. MEF NucleoFector Kit 2 (Amaxa) and program T-20 were used for nucleofection. A total of 2 × 10⁵ cells were transfected, and 5 × 10⁶ cells were seeded on gelatine in 10 cm² dishes. Cells were cultured in ESC media supplemented with 1.5 µg of Dox. Colonies arising after transfection were picked at day 24, trypsinized, and replated on gelatine. Dox was removed from the culture after several passages.

Lentiviral vector production, human iPSC generation, and immunostaining were performed as previously described (Papapetrou et al., 2009). Separate lentiviral constructs encoding full-length human Oct4, Sox2, Klf4, and cMyc linked by a P2A peptide to vEGFP, mCherrin, and mCerulean, respectively, were used. MRC-5 human embryonic fibroblasts (American Type Culture Collection [ATCC]) were transduced with supernatants of the four lentiviral vectors in the presence of 4 µg/ml polybrene for approximately 16 hr. Three days after transduction, the cells were plated at a density of 20,000 cells per 60 mm dish on a feeder layer of mitomycin-C-treated MEFs. Analysis of the four vector-encoded transcription factors’ expression by flow cytometry 3 days after transduction was used to identify groups with similar expression levels (mean fluorescence intensity) for comparison. The next day, the medium was switched to hESC medium supplemented with 6 ng/mL FGF2 and was replaced every day thereafter. Then, 16-18 days after transduction, colonies with hESC morphology were mechanically dissociated and transferred into 24-well plates on MEFs. Cells were thereafter passaged with dispase and expanded to establish hiPSC lines.

ACCESSION NUMBERS

The GEO accession number for the microarray data reported in this paper is GSE424563.

SUPPLEMENTAL INFORMATION

Supplemental information includes eight figures and five tables and can be found with this article online at doi:10.1016/j.celrep.2011.12.002.

LICENSING INFORMATION

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License (CC-BY-NC-ND; http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode).

ACKNOWLEDGMENTS

We would like to thank Hitoshi Niwa and Austin Smith for provision of materials; Laxmi M.S. Trunagari for technical assistance; Michel Sadelain for advice; and
Alfonso Martinez Arias, Sally Lowell, Val Wilson, and the entire Brickman and Ptashne labs for critical reading of this manuscript. This work was supported by the BBSRC (BB/C506605), Scottish Funding Council, the Medical Research Council (MRC G0701428) to J.M.B., the Intramural Research Program of the NIH, the National Institute on Aging (Z01AG AG000665, Z01AG000662) to M.S.H.K., and the New York Stem Cell Science (NYSSTEM) Program (C026407) to M.P.). F.H. was supported by a scholarship from the Algerian Government. J.M.B. is an MRC Senior Non-Clinical Research Fellow.

Received: October 17, 2011
Accepted: December 15, 2011
Published online: February 16, 2012

REFERENCES

Ang, Y.S., Tsai, S.Y., Lee, D.F., Monk, J., Su, J., Ratnakumar, K., Ding, J., Ge, Y., Darr, H., Chang, B., et al. (2011). Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 145, 183–197.

Baron, U., Gossen, M., and Bujard, H. (1997). Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res. 25, 2723–2729.

Bilodeau, S., Kagey, M.H., Frampton, G.M., Rahl, P.B., and Young, R.A. (2009). SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state. Genes Dev. 23, 2484–2489.

Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G., et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947–958.

Boyer, L.A., Plath, K., Zeitlinger, J., Brambink, T., Medeiros, L.A., Lee, T.I., Levine, S.S., Wernig, M., Tajonar, A., Ray, M.K., et al. (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349–353.

Brickman, J.M., Jones, C.M., Clements, M., Smith, J.C., and Beddington, R.S.P. (2000). Hex is a transcriptional repressor that contributes to anterior identity and suppresses Spemann organiser function. Development 127, 2303–2315.

Brickman, J.M., Clements, M., Tyrell, R., McNay, D., Woods, K., Warner, J., Stewart, A., Beddington, R.S., and Dattani, M. (2001). Molecular effects of novel mutations in Hex1/HESX1 associated with human pituitary disorders. Development 128, 5189–5199.

Cao, Y., Siegel, D., and Knöchel, W. (2006). Xenopus Pou factors of subclass V inhibit activin/nodal signaling during gastrulation. Mech. Dev. 123, 614–625.

Carter, M.G., Sharov, A.A., VanBuren, V., Dudekula, D.B., Carmack, C.E., Nelson, C., and Ko, M.S. (2005). Transcript copy number estimation using a mouse whole-genome oligonucleotide microarray. Genome Biol. 6, R61.

Chamberlain, S.J., Yee, D., and Magnuson, T. (2008). Polycistronic repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26, 1496–1505.

Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., and Smith, A. (2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113, 643–655.

Chen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V.B., Wong, E., Orlow, Y.L., Zhang, W., Jiang, J., et al. (2008). Externalization of integral signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133, 1106–1117.

Chew, J.L., Loh, Y.H., Zhang, W., Chen, X., Tam, W.L., Yeap, L.S., Li, P., Ang, Y.S., Lim, B., Robson, P., and Ng, H.H. (2005). Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol. Cell. Biol. 25, 6031–6046.

Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156.

Gill, G., and Ptashne, M. (1988). Negative effect of the transcriptional activator GAL4. Nature 334, 721–724.

Hall, J., Guo, G., Wray, J., Eyres, I., Nichols, J., Groteveld, L., Morfopoulos, S., Humphreys, P., Mansfield, W., Walker, R., et al. (2009). Oct4 and LIF/Stat3 additively induce Krüppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 5, 597–609.

Hay, D.C., Sutherland, L., Clark, J., and Burdon, T. (2004). Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 22, 225–235.

Hirai, H., Tani, T., Katoku-Kikyo, N., Keliner, S., Karian, P., Firma, M., and Kikyo, N. (2011). Radical acceleration of nuclear reprogramming by chromatin remodeling with the transactivation domain of MyoD. Stem Cells 29, 1349–1361.

Hobert, O. (2008). Regulatory logic of neuronal diversity: terminal selector genes and selector motifs. Proc. Natl. Acad. Sci. USA 105, 20067–20071.

Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K. (2009). Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771–775.

Kim, J., Chu, J., Shen, X., Wang, J., and Orkin, S.H. (2008). An extended transcriptional network for pluripotency of embryonic stem cells. Cell 132, 1049–1061.

Kim, J.B., Sebastiano, V., Wu, G., Araújo-Bravo, M.J., Sasse, P., Gentile, L., Ko, K., Ruau, D., Ehrich, M., van den Boom, D., et al. (2009). Oct4-induced pluripotency in adult neural stem cells. Cell 136, 411–419.

Laval, F., Acloque, H., Bertocchini, F., Macleod, D.J., Boast, S., Bachelard, E., Montillet, G., Thenot, S., Sang, H.M., Stem, C.D., et al. (2007). The Oct4 homologue Pou5f1 and Nanog regulate pluripotency in chicken embryonic stem cells. Development 134, 3549–3563.

Livigni, A., Villegas, S.N., Okonomopoulos, I., Rahman, A., Morrison, G.M., and Brickman, J.M. (2009). Differentiation of embryonic stem cells into anterior definitive endoderm. Curr. Protoc. Stem Cell Biol. Chapter 1, 1G, 3.

Loh, K.M., and Lim, B. (2011). A precarious balance: pluripotency factors as lineage specifiers. Cell Stem Cell 8, 363–369.

Loh, Y.H., Wu, Q., Chew, J.L., Vega, V.B., Zhang, W., Chen, X., Bourque, G., George, J., Leong, B., Liu, J., et al. (2006). The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38, 431–440.

Lunde, K., Belting, H.G., and Driever, W. (2004). Zebrafish pou5f1/pou2, homolog of mammalian Oct4, functions in the endoderm specification cascade. Curr. Biol. 14, 48–55.

Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 78, 7634–7638.

Morisson, G.M., and Brickman, J.M. (2006). Conserved roles for Oct4 homologues in maintaining multipotency during early vertebrate development. Development 133, 2011–2022.

Navarro, P., Chambers, I., Karwacki-Neisius, V., Chureau, C., Morey, C., Rougeulle, C., and Avner, P. (2008). Molecular coupling of Xist regulation and pluripotency. Science 321, 1693–1695.

Nichols, J., Zevnik, B., Anastasiassidi, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Schöler, H., and Smith, A. (1998). Formation of pluripotent stem cells in the mammalian embryo depends on the Pou transcription factor Oct4. Cell 95, 379–391.

Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-pou5f1 expression transfectants with a novel eukaryotic vector. Gene 107, 597–609.

Niwa, H., Burdon, T., Chambers, I., and Smith, A. (1998). Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12, R61.

Niwa, H., Leong, B., Liu, J., et al. (2006). The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38, 431–440.

Lunde, K., Belting, H.G., and Driever, W. (2004). Zebrafish pou5f1/pou2, homolog of mammalian Oct4, functions in the endoderm specification cascade. Curr. Biol. 14, 48–55.
generic transactivation function of Oct-3/4 in embryonic stem cells. Mol. Cell. Biol. 22, 1526–1536.

Ohashi, Y., Brickman, J.M., Furman, E., Middleton, B., and Carey, M. (1994). Modulating the potency of an activator in a yeast in vitro transcription system. Mol. Cell. Biol. 14, 2731–2739.

Palmieri, S.L., Peter, W., Hess, H., and Schöler, H.R. (1994). Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation. Dev. Biol. 166, 259–267.

Pan, G.J., Chang, Z.Y., Schöler, H.R., and Pei, D. (2002). Stem cell pluripotency and transcription factor Oct4. Cell Res. 12, 321–329.

Papapetrou, E.P., Tomishima, M.J., Chambers, S.M., Mica, Y., Reed, E., Menon, J., Tabar, V., Mo, Q., Studer, L., and Sadelain, M. (2009). Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc. Natl. Acad. Sci. USA 106, 12759–12764.

Pardo, M., Lang, B., Yu, L., Prosser, H., Bradley, A., Babu, M.M., and Choudhary, J. (2010). An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Cell Stem Cell 6, 382–395.

Pasini, D., Cloos, P.A., Walfridsson, J., Olsén, L., Bukowski, J.P., Johansen, J.V., Bak, M., Tommerup, N., Rappsilber, J., and Helin, K. (2010). JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 464, 306–310.

Ptashne, M. (2009). Binding reactions: epigenetic switches, signal transduction and cancer. Curr. Biol. 19, R234–R241.

Reim, G., Mizoguchi, T., Stainier, D.Y., Kikuchi, Y., and Brand, M. (2004). The POU domain protein spg (pou2/Oct4) is essential for endoderm formation in cooperation with the HMG domain protein casanova. Dev. Cell 6, 91–101.

Schoeftner, S., Sengupta, A.K., Kubicek, S., Mechtler, K., Spahn, L., Koseki, H., Jenuwein, T., and Wutz, A. (2006). Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J. 25, 3110–3122.

Sharov, A.A., Dudekula, D.B., and Ko, M.S. (2005). A web-based tool for principal component and significance analysis of microarray data. Bioinformatics 21, 2548–2549.

Sharov, A.A., Masui, S., Sharova, L.V., Piao, Y., Alia, K., Matoba, R., Xin, L., Niwa, H., and Ko, M.S. (2008). Identification of Pou5f1, Sox2, and Nanog downstream target genes with statistical confidence by applying a novel algorithm to time course microarray and genome-wide chromatin immunoprecipitation data. BMC Genomics 9, 269.

Smith, A.G., Heath, J.K., Donaldson, D.D., Wong, G.G., Moreau, J., Stahl, M., and Rogers, D. (1988). Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 336, 688–690.

Struhl, K. (1999). Fundamentally different logic of gene regulation in eukaryotes and prokaroytes. Cell 98, 1–4.

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676.

Wang, Y., Chen, J., Hu, J.L., Wei, X.X., Qin, D., Gao, J., Zhang, L., Jiang, J., Li, J.S., Liu, J., et al. (2011a). Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep. 12, 373–378.

Wang, X., Bai, L., Bryant, G.O., and Ptashne, M. (2011b). Nucleosomes and the accessibility problem. Trends Genet. 27, 487–492.

Williams, R.L., Hilton, D.J., Pease, S., Willson, T.A., Stewart, C.L., Gearing, D.P., Wagner, E.F., Metcalf, D., Nicola, N.A., and Gough, N.M. (1988). Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336, 684–687.

Yeat, L.S., Hayashi, K., and Surani, M.A. (2009). ERG-associated protein with SET domain (ESET)-Oct4 interaction regulates pluripotency and represses the trophoblast lineage. Epigenetics Chromatin 2, 12.

Ying, Q.L., Nichols, J., Chambers, I., and Smith, A. (2003). BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281–292.

Ying, Q.L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., and Smith, A. (2008). The ground state of embryonic stem cell self-renewal. Nature 453, 519–523.

Yuan, P., Han, J., Guo, G., Orlov, Y.L., Huss, M., Loh, Y.H., Yaw, L.P., Robson, P., Lim, B., and Ng, H.H. (2009). Eset partners with Oct4 to restrict extraembryonic trophoblast lineage potential in embryonic stem cells. Genes Dev. 23, 2507–2520.

Zamparini, A.L., Watts, T., Gardner, C.E., Tomlinson, S.R., Johnston, G.J., and Brickman, J.M. (2006). Hex acts with beta-catenin to regulate anteroposterior patterning via a Groucho-related co-repressor and Nodal. Development 133, 3709–3722.